To summarize current work identifying inflammatory components that underlie associations between obesityassociated type 2 diabetes and coronary artery disease.
INTRODUCTION
The prevalence of obesity continues to increase worldwide and with current trajectories obesity will burden healthcare systems for decades [1] . Obesity often triggers the inflammation that is believed to increase risk for many comorbidities, with greatest risk stemming from the simmering inflammation that underlies type 2 diabetes (T2D) and coronary artery disease (CAD) [2 & ,3 && ]. Obesity-associated inflammation is largely due to overproduction of proinflammatory cytokines by macrophages [4, 5] , B cells and T cells [6] [7] [8] [9] 10 && ], all of which are recruited to expanding adipose tissue. Immune cell-mediated inflammation reinforces a proinflammatory balance of adipokines, or adipocyte cytokines, which are also increased in expanding adipose tissue [11] . This combination of cytokines from adipose-associated immune cells and adipokines promotes metabolic dysregulation that includes insulin resistance and T2D [12 & ,13] . The proinflammatory cytokine profile in obesity likely spills over into the circulation and predicts increased risk for CAD [14, 15] , pulmonary diseases [16] [17] [18] and cancer [19] . Inflammation may thereby link seemingly disparate comorbidities of obesity.
Although mouse models have enabled substantial progress over the last decade in describing immune compartment contributions to metabolic dysfunction, an understanding of the role inflammation plays in human obesity and associated metabolic disease remains rudimentary. Recent findings from human studies reviewed herein highlight ongoing progress in our understanding of inflammation as a driver of obesity-associated disease with emphasis on CAD.
OBESITY-ASSOCIATED INFLAMMATION AND IMMUNE CELLS IN TYPE 2 DIABETES
A major advance in metabolic research came with the understanding of obesity as a chronic, low-grade inflammatory state, which differs from the immune response to infection but involves well understood modulators of nutrient storage and efflux pathways [8, 20, 21 & ]. Observations that activated macrophages within adipose tissue produce the majority of adipose-associated proinflammatory cytokines, and these cytokines promote insulin resistance [4, 5] , provoked the current focus on multiple types of immune cells in metabolic research and founded the field of 'Immunometabolism'. Extensive genetic, dietary and pharmacologic interventions in mouse models in parallel with observations from human studies identified a causal link between obesity-associated inflammation and metabolic disease [22, 23] þ T helper 17 cell function in samples from T2D but not from obese, nondiabetic subjects. Although anti-inflammatory functions of B cells and regulatory T cells (Tregs) have also been well defined, these functions appear to be diminished in obesity [8, [30] [31] [32] . For example, B cells from lean, 'metabolically healthy' humans and mice release significant amounts of the anti-inflammatory cytokine interleukin-10, but B cell interleukin-10 is severely downregulated in response to obesity/insulin resistance/ T2D [10 && ,33] . This shift to a potentially pathogenic, proinflammatory B cell cytokine profile may mechanistically underlie demonstrations that B cell-null mice fed a high-fat diet (HFD) are equally obese but less prone to obesity-associated insulin resistance and other metabolic disturbances. Anti-inflammatory CD4
þ Tregs are similarly underrepresented in obese/insulin resistant mice and T2D humans, in part because of lower numbers of Tregs [8, 34] but also likely due to suppression of anti-inflammatory interleukin-10 production [35 & ], although clarification is needed in follow-up studies with human samples. Despite overall similarities in roles for B and T cells in human and mouse T2D, a more comprehensive assessment of T cells in obesity suggests fundamental differences in obesity-associated inflammation between humans and mice: obese mice have predominantly CD8 and T helper 1 inflammatory responses with minor changes in T helper 17 cells [8, 9] , whereas in obese humans, the T helper 17 axis dominates T cell-mediated inflammation [10 
T HELPER 17 CELLS IN OBESITY AND TYPE 2 DIABETES
The importance of T cell cytokines, such as interferon gamma (IFNg) and interleukin-17 in obesity is less appreciated than thoroughly examined, classical 'diabetogenic' cytokines (e.g., tumor necrosis factor-a, interleukin-6 and interleukin-1b) [22] . T helper 17 cells, the dominant source of interleukin-17, are
KEY POINTS
Obesity/insulin resistance causes a shift towards proinflammatory T helper 17 immune response in humans, which differs from the T helper 1/CD8 þ T cell dominance of murine obesity/insulin resistance.
Proinflammatory T cell responses may underlie increased risk for obesity-associated CAD.
Classifying patients within obese cohorts by depotspecific immune responses or by specific adipose depot volume will assist in developing criteria for obesityassociated inflammation, CAD risk and severity.
instead recognized primarily for roles in clearance of select pathogens and for detrimental effects in autoimmune diseases, such as multiple sclerosis (mouse experimental autoimmune encephalitis) [38
Data showing that interleukin-6 and interleukin-1b drive T helper 17 differentiation [40, 41] are part of an emerging appreciation of T helper 17 expansion in obesity-associated insulin resistance/T2D. Recently, leptin, an adipokine generally increased in obesity/ insulin resistance, was shown to also support T helper 17 expansion [42 & ,43] . Overall, the relationship between increased interleukin-6/interleukin-1b/leptin and increased T helper 17 differentiation, coupled with the importance of T helper 17s in autoimmune diseases, may explain clinical evidence that obesity predisposes people to increased risk for inflammation-mediated autoimmune diseases, including psoriasis, rheumatoid arthritis [44] , lupus [45] and multiple sclerosis [7, 46] . Despite these likely mechanistic links between obesity-associated inflammation and T helper 17 cells, the T helper 17 signature cytokines interleukin-17 and interleukin-22 have been more or less dismissed in mouse models of obesity and T2D, in part because interleukin-17 þ cells (likely T helper 17s) infiltrate murine subcutaneous rather than visceral adipose tissue in response to HFD [47] , or T helper 17s dominate only after obesity/insulin resistance is established [48] . Interleukin-17 gene deletion caused an abnormal weight gain on both low fat or HFD compared with wild type controls, precluding a straight-forward interpretation of roles for T helper 17 cells in obese knockout animals [49] . This lack of strong data for interleukin-17/T helper 17 dominance in obesity-associated insulin resistance in mice has moderated excitement over possible functions of T helper 17s in human obesity/insulin resistance/T2D, although several One example of such an approach is long-term (9-month) HFD feeding of genetically homogeneous C57BL6 mice, which surprisingly revealed four different metabolic response groups. These groups include the lean/insulin resistant and obese/insulin sensitive groups that are generally absent (or even culled) following standard 12-16-week feeding protocols [53] . Measuring cytokines from these metabolic groups of mice or investigation of strains of mice with resistance to diet-induced obesity [54] could facilitate progress in understanding mechanisms underlying immune cell/cytokine involvement in patients.
OBESITY, INFLAMMATION AND ASSOCIATED CORONARY ARTERY DISEASE
Western diet together with obesity, T2D, hypertension, dyslipidemia, physical inactivity and increasing average age are believed to be primary causes of CAD and CAD-associated heart failure, the leading cause of death in T2D individuals [55] . The role of inflammation in CAD has been appreciated for decades, with a relatively early appreciation that local immune cell infiltrates characterize CAD and can specifically predict risk for fatal outcome [56, 57] . Immune cell infiltrates occur downstream of endothelial dysfunction, which promotes lipoprotein transcytosis from the plasma into the vessel intima. Subsequent immune cell infiltration/activation thereby links endothelial changes to cardiovascular disease/CAD [58, 59] . Teasing out the complex interactions among obesity, CAD and T2D is a daunting endeavor, but the appreciation of inflammation as a critical mediator primes the field to expand the findings above thus spur fundamentally new clinical approaches.
Documented roles for macrophages, T cells and B cells in CAD suggest that obesity-associated inflammation bridges immune cell function and CAD [60] [61] [62] [63] [64] [65] [66] . Macrophages were the first immune cell recognized to play critical roles in the development of atherosclerosis, from early fatty streak formation through progression to vulnerable plaques. Mechanisms of macrophage involvement in CAD include the ability to form foam cells, and to secrete high amounts of proinflammatory, pro-CAD cytokines such as tumor necrosis factor-a, interleukin-1b, interleukin-6 and interleukin-8 [60, [67] [68] [69] [70] [71] [72] .
Proinflammatory T cells also play critical roles in the endothelial dysfunction that precedes CAD [61] [62] [63] [64] [65] 
þ -associated cytokines, ameliorates disease in mouse models [73] , independently indicating that T helper 1s promote CAD. Similarly, interleukin-17, the major cytokine produced by T helper 17s, is important for the recruitment of macrophages to developing atherosclerotic lesions [61,74,75 & ], and both CD4 þ and CD8 þ T cells characterize unstable plaques (71) (72) (73) (74) . Thus, multiple lines of evidence suggest that proinflammatory T cells support obesity-associated atherosclerosis and may link CAD to T2D.
B cells are more recently appreciated mediators of CAD, although their roles are more complex than the proatherogenic functions of macrophages and T cells. B cell depletion protects against CAD in model animals [66] , suggesting that B cells are pathogenic. In contrast, some studies show that B cells protect against atherosclerosis [76] . The latter interpretation is consistent with the demonstration that removal of the normal splenic reservoir of B cells renders patients more susceptible to CAD [77] . Although exact mechanisms are not known, these seemingly contradictory findings on roles for B cells in atherosclerosis may be explained by demonstrations that B cells can initially protect against inflammatory disease, but then can change their activity, promoting pathogenesis [10 && ,34,78] . For example, the loss of B cell interleukin-10 in T2D discussed above, coupled with a T2D-associated increase in the ability of B cells to produce CAD-associated interleukin-8 [72, 79] , is consistent with a disease-associated gain of pathogenic B cell function. B cells also promote pericardial adipose tissue expansion and inflammation in a mouse model of obesity-associated insulin resistance [10 && ]. Taken together, these reports suggest that B cells from obese/insulin resistant patients support CAD-associated inflammation through multiple mechanisms, such as promoting proinflammatory cytokine production including high interleukin-8 and low interleukin-10 release [34, 69, 80, 81] , supporting adipose tissue expansion in obesity [10 && ] and promoting proinflammatory T helper 17 cells [6,10 && ,82] . Both the activities of individual immune cells and the cross-talk among immune cell subsets raise the clinically critical possibility that immunomodulatory drugs, such as the generally well tolerated B cell depletion drug rituximab [83, 84] , may have unappreciated efficacy in the prevention of obesity-associated CAD [85] .
THE ROLE OF PERICARDIAL ADIPOSE TISSUE IN LOCAL INFLAMMATION AND CORONARY ARTERY DISEASE
Although adipose depots all increase in volume with obesity, fat deposits in different anatomical regions show depot-associated levels of immune cell infiltration and inflammation, and thus differentially associate with disease. To generalize, subcutaneous adipose tissue is more metabolically 'protective', whereas pericardial and other visceral depots are highly correlated with risk for obesity-associated disease, including CAD [86] [87] [88] . The recognition that pericardial adipose tissue (pAT) physiology, which includes pAT inflammation, is a critical mediator of CAD significantly departs from the outdated assumption that pAT expansion is an uninteresting epiphenomenon of both obesityindependent and obesity-associated CAD.
Numerous analyses point to the importance of pAT expansion and concomitant inflammation in obesity/insulin resistance-associated CAD. pAT from patients with CAD has increased inflammatory hallmarks compared with pAT from patients undergoing non-CAD heart procedures [72, [89] [90] [91] . Notably, pAT volume also associates with systemic inflammation, as measured by interleukin-6 and C-reactive protein levels [92] . Also, CAD is more tightly associated with the amount of pAT in lean individuals than with a variety of more 'accepted' CAD risk factors, including body fat distribution [93] . pAT volume is a strong independent risk factor for CAD severity [88] , and positively associates with calcified coronary plaque [94, 95] which suggests that pAT may exert local toxic effects on the coronary vasculature [96] . Thus, it is unsurprising that the amount of pAT negatively correlates with cardiac output and stroke volume [97] . Additionally, epidemiological studies show that relatively high pAT volume (>300 cm 3 ) associates with a four-fold increased risk of CAD, whereas smoking and T2D increase CAD risk 1.6-fold and three-fold, respectively [98] . Prospective studies revealed that the volume of epicardial adipose tissue, the depot that literally coats the myocardium, is predictive of obstructive CAD even before patients develop overt disease [99 & ,100,101] . Finally, perhaps the most convincing human evidence linking obesity, inflammation and CAD is analysis of monozygotic twins discordant for obesity. This study found that the obese twin had a greater epicardial adipose tissue volume, and that C-reactive protein, one surrogate for systemic inflammation, was the only one of several factors measured that significantly associated with epicardial adipose tissue volume. These studies support the conclusion that inflammation and epicardial adipose tissue volume predict risk for CAD [102 & ,103] and highlight the urgency of a more comprehensive analysis of pAT physiology focused FIGURE 2. Depiction of regional adipose tissue deposition in human body and obesity-associated gene and cytokine profiles. Adipose tissue depots that preferentially expand in metabolically unhealthy (inflammatory) responses include pericardial (epicardial and interstitial) and visceral depots. Adipose tissue that preferentially expands in metabolically healthy obese individuals includes widespread subcutaneous depots. Shown are upregulated or downregulated genes, adipokines, or cytokines associated with obesity comorbidities, T2D and CAD. CAD, coronary artery disease; COA1a, cytochrome oxidase assembly 1a; CRP, C-reactive protein; FABP4, fatty acid binding protein 4; IL, interleukin; PPARg, peroxisome proliferator-activator receptor g; PR-DM16, positive regulatory domain 16; RANTES, regulated on activation normal T cell expressed and secreted; S100A9, soluble protein 100 a 9; TNFa, tumor necrosis factor-a; T2D, type 2 diabetes; UCP-1, uncoupling protein 1.
on inflammation to advance the long-term goal of countering CAD pathogenesis. Together, the associations between pAT inflammation and CAD/impaired cardiovascular function, plus the known roles of obesity in adipose tissue volume and proinflammatory immune cell function [4] [5] [6] [7] 10 && , 33, 34, 47, 72, 79, 89, 91, 104] , frame the idea that obesity-associated changes in pAT physiology link obesity and CAD and are further exacerbated in the presence of insulin resistance. However, one gap in the pAT analyses is that 'pAT' is often imprecisely defined and can denote the epicardial adipose tissue that coats the heart, the interstitial adipose tissue that coats the outside of the pericardial membrane (thus, does not directly touch the heart) or both. Both heart-proximal depots (Fig. 2) are linked to local and systemic inflammation, although each is also somewhat distinct from the other [72,89-92,105,106 & ]. Epicardial adipose tissue may disproportionately impact CAD because of a shared circulation with the myocardium [107] . Regardless, a comparison of physiology of epicardial fat, interstitial fat and blood from the same individual is essential to comprehensively understand inflammation in heart-proximal adipose tissue, and will be vital for identifying pAT signatures in a more accessible tissue.
A clinically important, yet unappreciated aspect of studies on obesity, inflammation and CAD is the possibility that fundamentally different mechanisms drive CAD in lean/insulin sensitive compared to obese/insulin sensitive or obese/insulin resistant patients. This novel prospect is raised by our recent work showing mechanisms of periodontitis, another common comorbidity in obesity/insulin resistance, significantly differ between lean/ insulin sensitive and obese/insulin resistant mice [108] . Lean mice developed periodontitis through a B cell-independent process, whereas periodontitis development in obese/insulin resistant mice was highly B cell-dependent. Obesity-associated inflammatory responses in periodontitis and CAD are inadequately studied in humans, although one cross-sectional study of obese subjects with and without periodontitis identified that both obesity and periodontitis increased risk for cardiovascular disease [109 & ]. Future identification of correlates of CAD over a range of metabolic status with subsequent mechanistic analyses will be needed to determine whether the currently similar standard of care for CAD in lean and obese/insulin resistant patients is the best approach.
CONCLUSION
Our developing appreciation of links among obesity, inflammation and CAD will require multiple complementary approaches to leverage new concepts into translatable outcomes. Careful characterization of human patients, particularly analysis of adipose tissue distribution by measures as simple as waist-to-hip ratio, will be needed to stratify subjects that are most likely obese/metabolically healthy from those that are obese/metabolically unhealthy [93, 110] . Notably, subjects with T2D are most effectively analyzed as a unique cohort, rather than being lumped into the 'obese/insulin resistant' category. Use of models that more closely parallel human disease will increase the translational significance of studies. A call for simple analysis of metabolic status in all clinical drug trials (e.g., HbA1c) would identify drugs with potential efficacy against obesityassociated CAD, although incurring minimal extra cost. Similarly, collection of (at least) serum and peripheral blood mononuclear cells from all obesity or CAD-associated clinical trials would provide samples for testing of new possibilities, such as T helper 17 dominance. Concepts developed in human sample studies, with further testing in models to refine concepts, will integrate the strengths of both bench and bedside research to allow the field to exploit our understanding of obesity-associated inflammation for clinical gains over the short term. 
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